What is Salarius Pharmaceuticals, Inc.'s earnings per share (EPS)?

Salarius Pharmaceuticals, Inc. (SLRX) reported diluted earnings per share of -$129.10 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Salarius Pharmaceuticals, Inc. (SLRX) Financials

SLRX

FY2025 annual

Net Income $12.5M +124.4% YoY

EPS (Diluted) -$129.10 YoY not available

Free Cash Flow -$5.4M -19.4% YoY

Operating Cash Flow -$4.8M -6.7% YoY

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2026, ended Mar 31, 2026 Reported May 8, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q1 FY2026, filed May 8, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the SLRX SEC filings page.

This page shows Salarius Pharmaceuticals, Inc. (SLRX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI SLRX FY2025 2026-10-03

The reported business remains research-led: operations lose cash, reported net income is disconnected from operations, and financing supplies cash.

FY2025 net income of $12.5M sat beside an operating loss of $12.6M, so reported profitability did not come from core operations. Operating cash flow of -$4.8M confirms that accounting income was not converting into cash.

The funding pattern is the key balance-sheet mechanic: financing provided $12.3M in FY2025 while operating activities used $4.8M. Those flows lifted total assets to $11.1M, while liabilities reached $5.2M; the balance sheet is being rebuilt largely through external funding rather than internally generated cash.

Liquidity is not absent: the reported cash-and-investment comparison equaled 26.6 months of FY2025 operating outflow. The current ratio improved from 2.0x in FY2024 to 2.1x in FY2025, but free cash flow was -$5.4M after $577K of capital spending, keeping funding needs active.

Financial Health Signals

Financial health score not available

Salarius Pharmaceuticals, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

3/6

Salarius Pharmaceuticals, Inc. passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, all 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

$0.39used

For every $1 of reported earnings, Salarius Pharmaceuticals, Inc. used $0.39 of operating cash (-$4.8M OCF vs $12.5M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$2.3M

YoY-32.6%

Salarius Pharmaceuticals, Inc.'s EBITDA was -$2.3M in Q1 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 32.6% from the same quarter a year earlier.

Net Income

-$2.2M

YoY-30.1%

Salarius Pharmaceuticals, Inc. reported -$2.2M in net income in Q1 2026. This represents a decrease of 30.1% from the same quarter a year earlier.

EPS (Diluted)

-$4.18

Salarius Pharmaceuticals, Inc. earned -$4.18 per diluted share (EPS) in Q1 2026.

Revenue

Not reported for Q1 2026.

Cash & Balance Sheet

Cash & Debt

$7.8M

YoY+334.9%

QoQ-27.0%

5Y CAGR-26.6%

10Y CAGR-21.2%

Salarius Pharmaceuticals, Inc. held $7.8M in cash as of Q1 2026; long-term debt is not reported for that period.

Shares Outstanding

531,968

5Y CAGR-58.8%

10Y CAGR-29.7%

Salarius Pharmaceuticals, Inc. had 531,968 shares outstanding in Q1 2026.

Free Cash Flow

Not reported for Q1 2026.

Dividends Per Share

Not reported for Q1 2026.

Margins & Returns

Return on Equity

-57.4%

YoY+2705.9pp

Salarius Pharmaceuticals, Inc.'s ROE was -57.4% in Q1 2026, measuring profit generated per dollar of shareholder equity. This is up 2705.9 percentage points from the same quarter a year earlier.

Gross Margin

Not reported for Q1 2026.

Operating Margin

Not reported for Q1 2026.

Net Margin

Not reported for Q1 2026.

Capital Allocation

R&D Spending

$750K

YoY+892.7%

Salarius Pharmaceuticals, Inc. invested $750K in research and development in Q1 2026. This represents an increase of 892.7% from the same quarter a year earlier.

Share Buybacks

Not reported for Q1 2026.

Capital Expenditures

Not reported for Q1 2026.

SLRX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SLRX quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15
Revenue	N/A	N/A	N/A	N/A	$0-100.0%	$1.8M-64.8%	$5.2M+51.0%	$3.5M+77.6%	$2.0M+53.1%	$1.3M+26.1%	$1.0M	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$431K-15.0%	$507K-23.6%	$663K	$0
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$1.5M+98.0%	$768K+120.7%	$348K	$0
R&D Expenses	N/A	$368K-52.2%	$770K-89.3%	$7.2M-54.7%	$15.8M+85.3%	$8.5M+23.6%	$6.9M+72.0%	$4.0M+212.1%	$1.3M-92.4%	$17.0M-16.6%	$20.4M+59.8%	$12.7M
SG&A Expenses	N/A	$3.7M-24.9%	$5.0M-13.2%	$5.7M-19.9%	$7.1M+16.9%	$6.1M0.0%	$6.1M-20.8%	$7.7M+228.4%	$2.3M-87.3%	$18.5M-6.8%	$19.9M+20.6%	$16.5M
Operating Income	N/A	-$12.6M-120.0%	-$5.7M+55.5%	-$12.9M+59.5%	-$31.8M-148.5%	-$12.8M-64.6%	-$7.8M+5.8%	-$8.3M-390.6%	-$1.7M+95.1%	-$34.7M+12.9%	-$39.9M-36.5%	-$29.2M
EBITDA	N/A	-$12.6M-120.0%	-$5.7M+55.5%	-$12.9M+59.5%	-$31.8M-148.8%	-$12.8M-64.7%	-$7.8M+4.5%	-$8.1M-388.0%	-$1.7M+95.2%	-$34.4M+13.1%	-$39.6M-35.8%	-$29.2M
Income Tax	N/A	$0	N/A	N/A	N/A	N/A	N/A	$0	N/A	N/A	N/A	N/A
Net Income	N/A	$12.5M+124.4%	$5.6M-55.5%	$12.5M+139.7%	-$31.6M-147.6%	-$12.8M-73.7%	-$7.4M-6.0%	-$6.9M-315.4%	-$1.7M+95.2%	-$34.4M+12.8%	-$39.5M-35.5%	-$29.1M
EPS (Basic)	N/A	-$129.10-85.6%	-$69.54-126.2%	-$30.74-106.6%	-$14.88-92.7%	-$7.72-1444.0%	-$0.50	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	—	-$129.10	-$69.54	-$30.74	-$14.88-92.7%	-$7.72	-$0.50	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	96,967	80,184	408,078	2M+28.4%	2M	16M	N/A	N/A	N/A	N/A	N/A

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
R&D Expenses	$750K+892.7%	N/A	$62K-54.9%	$116K-45.7%	$76K-68.9%	N/A	$137K-86.8%	$214K-90.9%
SG&A Expenses	$1.5M-6.6%	N/A	$833K-4.1%	$849K-32.2%	$1.6M+7.5%	N/A	$869K-41.9%	$1.3M-22.6%
Operating Income	-$2.3M-32.9%	N/A	-$895K+11.1%	-$966K+34.2%	-$1.7M+3.0%	N/A	-$1.0M+60.3%	-$1.5M+63.0%
EBITDA	-$2.3M-32.6%	N/A	N/A	N/A	-$1.7M+3.0%	N/A	N/A	N/A
Net Income	-$2.2M-30.1%	N/A	-$873K+10.1%	-$958K+32.8%	-$1.7M+0.3%	N/A	-$972K+60.2%	-$1.4M+63.3%
EPS (Basic)	-$4.18+98.3%	N/A	-$1.81+84.1%	-$0.45+81.0%	-$240.07-7241.6%	N/A	-$11.38-118.4%	-$2.37+79.3%
EPS (Diluted)	-$4.18	N/A	-$1.81	-$0.45	-$240.07	N/A	-$11.38	-$2.37
Diluted Shares (Avg)	531,968	N/A	481,587	2M	7,121	N/A	85,458	600,417

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.

SLRX Balance Sheet

SLRX quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15
Total Assets	$11.1M+265.8%	$3.0M-54.1%	$6.6M-55.0%	$14.7M-64.1%	$40.8M+63.8%	$24.9M+79.4%	$13.9M+110.1%	$6.6M-81.1%	$35.0M-44.6%	$63.2M-33.5%	$95.1M
Current Assets	$11.0M+267.7%	$3.0M-54.2%	$6.5M-55.1%	$14.5M-51.9%	$30.2M+90.9%	$15.8M+236.5%	$4.7M-26.4%	$6.4M-81.5%	$34.5M-44.7%	$62.5M-32.3%	$92.2M
Cash & Equivalents	$10.7M+339.9%	$2.4M-58.7%	$5.9M-51.3%	$12.1M-58.6%	$29.2M+162.8%	$11.1M+197.4%	$3.7M+15.8%	$3.2M-83.2%	$19.2M-14.9%	$22.5M-66.3%	$66.8M
Short-Term Investments	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$187K-56.7%	$432K-4.9%	$454K	$0
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$10K-4.3%	$10K-14.7%	$12K	$0
Long-Term Investments	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	$0-100.0%	$8.9M0.0%	$8.9M0.0%	$8.9M	$0	N/A	N/A	N/A
Total Liabilities	$5.2M+241.9%	$1.5M+16.3%	$1.3M-69.5%	$4.3M+102.1%	$2.1M-23.9%	$2.8M-16.3%	$3.3M-58.0%	$7.9M-79.2%	$37.9M+872.2%	$3.9M+35.5%	$2.9M
Current Liabilities	$5.2M+241.9%	$1.5M	N/A	N/A	N/A	N/A	N/A	$1.1M-81.1%	$5.8M+50.4%	$3.9M+36.6%	$2.8M
Non-Current Liabilities	$0	$0	N/A	N/A	N/A	N/A	N/A	$6.8M-78.8%	$32.0M+381485.2%	$8K-72.0%	$30K
Total Equity	$5.9M+289.6%	$1.5M-71.4%	$5.3M-49.1%	$10.4M-73.2%	$38.7M+74.7%	$22.2M+109.4%	$10.6M+932.4%	-$1.3M+56.2%	-$2.9M-104.9%	$59.3M-35.7%	$92.2M
Retained Earnings	-$94.4M-15.3%	-$81.9M-7.3%	-$76.3M-19.7%	-$63.8M-98.2%	-$32.2M-65.7%	-$19.4M-60.9%	-$12.1M-134.9%	-$5.1M+95.4%	-$111.1M-44.9%	-$76.6M-106.3%	-$37.2M

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Total Assets	$8.4M+260.1%	$11.1M+265.8%	$6.1M+58.0%	$1.4M-60.8%	$2.3M-52.1%	$3.0M-54.1%	$3.9M-54.1%	$3.6M-70.5%
Current Assets	$8.4M+262.6%	$11.0M+267.7%	$6.1M+58.7%	$1.4M-61.3%	$2.3M-52.3%	$3.0M-54.2%	$3.8M-54.1%	$3.5M-70.6%
Cash & Equivalents	$7.8M+334.9%	$10.7M+339.9%	$4.8M+46.5%	$795K-75.7%	$1.8M-58.9%	$2.4M-58.7%	$3.3M-56.7%	$3.3M-71.6%
Total Liabilities	$4.5M+99.6%	$5.2M+241.9%	$1.8M+97.8%	$2.2M+88.6%	$2.3M+84.5%	$1.5M+16.3%	$935K-59.7%	$1.2M-67.6%
Current Liabilities	$4.5M	$5.2M+241.9%	N/A	N/A	N/A	$1.5M	N/A	N/A
Non-Current Liabilities	$0	$0	N/A	N/A	N/A	$0	N/A	N/A
Total Equity	$3.9M+6167.4%	$5.9M+289.6%	$4.2M+45.3%	-$830K-134.9%	$62K-98.3%	$1.5M-71.4%	$2.9M-51.9%	$2.4M-71.8%
Retained Earnings	-$96.7M-15.6%	-$94.4M-15.3%	-$85.5M-6.2%	-$84.6M-6.4%	-$83.6M-7.1%	-$81.9M-7.3%	-$80.5M-6.6%	-$79.5M-8.9%

Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Accounts Receivable, Long-Term Investments, Goodwill, Long-Term Debt.

SLRX Cash Flow Statement

SLRX quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15
Operating Cash Flow	-$6.5M	-$4.8M-6.7%	-$4.5M+64.8%	-$12.8M+27.0%	-$17.6M-72.5%	-$10.2M+1.1%	-$10.3M+11.0%	-$11.6M-377.2%	$4.2M+115.1%	-$27.7M+13.5%	-$32.1M-54.5%	-$20.7M
Depreciation & Amortization	N/A	$7K+61.6%	$4K-56.0%	$10K+50.5%	$7K-65.2%	$19K+6.2%	$18K-85.8%	$127K+651.7%	$17K-94.8%	$325K+17.1%	$277K+455.8%	$50K
Stock-Based Compensation	N/A	$219K-20.0%	$274K-47.8%	$525K-34.1%	$797K+42.5%	$559K+75.0%	$319K-57.5%	$752K+2327.6%	$31K-99.3%	$4.2M-35.8%	$6.6M-0.4%	$6.6M
Capital Expenditures	N/A	$577K	$0	N/A	N/A	$0-100.0%	$3K	$0	$0-100.0%	$113K-79.7%	$559K+110.6%	$266K
Free Cash Flow	N/A	-$5.4M-19.4%	-$4.5M	N/A	N/A	-$10.2M+1.1%	-$10.3M+10.9%	-$11.6M-377.2%	$4.2M+115.0%	-$27.8M+14.6%	-$32.6M-55.2%	-$21.0M
Investing Cash Flow	N/A	$765K	$0	$0+100.0%	-$1.5M	$0+100.0%	-$3K-100.0%	$5.6M	$0-100.0%	$24.5M+300.1%	-$12.2M+55.1%	-$27.3M
Financing Cash Flow	$11.8M	$12.3M+1064.0%	$1.1M-84.0%	$6.6M+234.1%	$2.0M-93.0%	$28.3M+59.9%	$17.7M+394.3%	$3.6M+149.4%	$1.4M+54431.0%	$3K-88.1%	$22K-100.0%	$80.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$134K	$0	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$615K	N/A	N/A	N/A

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Operating Cash Flow	-$2.9M-144.5%	-$1.1M-53.1%	-$1.6M-21.4%	-$862K+19.6%	-$1.2M+12.7%	-$743K+50.9%	-$1.4M+63.8%	-$1.1M+75.7%
Depreciation & Amortization	$6K+435.6%	N/A	N/A	N/A	$1K-0.1%	N/A	N/A	N/A
Stock-Based Compensation	$213K+535.3%	N/A	N/A	N/A	$34K-56.7%	N/A	N/A	N/A
Investing Cash Flow	N/A	$965K	N/A	N/A	N/A	$0	N/A	N/A
Financing Cash Flow	$0-100.0%	$6.1M+5775.7%	$5.9M+328.5%	-$141K-400.9%	$546K+415.8%	-$107K+36.9%	$1.4M+745.7%	-$28K-100.4%

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

SLRX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SLRX quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	77.9%+17.7pp	60.3%+25.8pp	34.4%	N/A
Operating Margin	N/A	N/A	N/A	N/A	-696.3%	-148.8%	-238.5%	-86.3%	-2724.7%	-3946.5%	N/A
Net Margin	N/A	N/A	N/A	N/A	-693.8%	-140.5%	-200.2%	-85.6%	-2701.7%	-3907.7%	N/A
Return on Equity	212.6%-156.5pp	369.1%+131.9pp	237.2%+541.5pp	-304.4%-271.4pp	-33.0%+0.2pp	-33.2%+32.4pp	-65.5%	N/A	N/A	-66.6%-35.0pp	-31.6%
Return on Assets	113.2%-71.4pp	184.6%-5.8pp	190.4%+406.1pp	-215.7%-184.5pp	-31.3%-1.8pp	-29.5%+20.4pp	-49.9%-24.7pp	-25.2%+73.2pp	-98.4%-35.9pp	-62.5%-31.8pp	-30.6%
Current Ratio	2.13+0.1x	1.98	N/A	N/A	N/A	N/A	N/A	5.76-0.1x	5.91-10.2x	16.06-16.3x	32.40
Debt-to-Equity	0.88-0.1x	1.00+0.8x	0.25-0.2x	0.41+0.4x	0.05-0.1x	0.13-0.2x	0.31	N/A	N/A	0.070.0x	0.03
Asset Turnover	N/A	N/A	N/A	0.000.0x	0.05-0.2x	0.210.0x	0.250.0x	0.29+0.3x	0.040.0x	0.020.0x	0.00
FCF Margin	N/A	N/A	N/A	N/A	-554.3%	-197.1%	-334.2%	214.1%	-2184.0%	-3226.7%	N/A

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'2410-Q
Return on Equity	-57.4%+2705.9pp	N/A	-20.6%+12.7pp	N/A	-2763.3%-2716.3pp	N/A	-33.2%+6.9pp	-60.0%-13.9pp
Return on Assets	-26.4%+46.7pp	N/A	-14.3%+10.9pp	-68.8%-28.7pp	-73.1%-38.0pp	N/A	-25.2%+3.9pp	-40.1%-7.9pp
Current Ratio	1.84	2.13+0.1x	N/A	N/A	N/A	1.98	N/A	N/A
Debt-to-Equity	1.17-35.6x	0.88-0.1x	0.44+0.1x	N/A	36.81+36.5x	1.00+0.8x	0.32-0.1x	0.50+0.1x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Salarius Pharmaceuticals, Inc. SLRX	FY2025	N/A	$12.5M	N/A	$2.7M	—
GT Biopharma Inc. GTBP	FY2025	N/A	-$28.4M	N/A	$12.7M	—
PROTAGENIC THERAPEUTICS PTIX	FY2026	$0	$1.4M	N/A	$1.4M	—
LIPELLA PHARMS INC LIPO	FY2024	$536K	-$5.0M	N/A	N/A	—
Indaptus Therapeutics, Inc. INDP	FY2025	N/A	-$20.8M	N/A	$350.4M	—
Scinai Immunotherapeutics Ltd. SCNI	FY2025	$1.3M	-$8.3M	N/A	$1.0M	45/100

Where Salarius Pharmaceuticals, Inc. Ranks

Frequently Asked Questions

Is Salarius Pharmaceuticals, Inc. profitable?

Yes, Salarius Pharmaceuticals, Inc. (SLRX) reported a net income of $12.5M in fiscal year 2025.

What is Salarius Pharmaceuticals, Inc.'s EBITDA?

Salarius Pharmaceuticals, Inc. (SLRX) had EBITDA of -$12.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Salarius Pharmaceuticals, Inc.'s return on equity (ROE)?

Salarius Pharmaceuticals, Inc. (SLRX) has a return on equity of 212.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Salarius Pharmaceuticals, Inc.'s free cash flow?

Salarius Pharmaceuticals, Inc. (SLRX) recorded an outflow of $5.4M in free cash flow during fiscal year 2025. This represents a -19.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Salarius Pharmaceuticals, Inc.'s operating cash flow?

Salarius Pharmaceuticals, Inc. (SLRX) recorded an outflow of $4.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Salarius Pharmaceuticals, Inc.'s total assets?

Salarius Pharmaceuticals, Inc. (SLRX) had $11.1M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Salarius Pharmaceuticals, Inc.'s capital expenditures?

Salarius Pharmaceuticals, Inc. (SLRX) invested $577K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Salarius Pharmaceuticals, Inc. spend on research and development?

Salarius Pharmaceuticals, Inc. (SLRX) invested $368K in research and development during fiscal year 2025.

How many shares does Salarius Pharmaceuticals, Inc. have outstanding?

Salarius Pharmaceuticals, Inc. (SLRX) had 8,006 shares outstanding as of fiscal year 2025.

What is Salarius Pharmaceuticals, Inc.'s current ratio?

Salarius Pharmaceuticals, Inc. (SLRX) had a current ratio of 2.13 as of fiscal year 2025, which is generally considered healthy.

What is Salarius Pharmaceuticals, Inc.'s debt-to-equity ratio?

Salarius Pharmaceuticals, Inc. (SLRX) had a debt-to-equity ratio of 0.88 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Salarius Pharmaceuticals, Inc.'s return on assets (ROA)?

Salarius Pharmaceuticals, Inc. (SLRX) had a return on assets of 113.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does Salarius Pharmaceuticals, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Salarius Pharmaceuticals, Inc. (SLRX) held $10.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $4.8M over that year. Dividing the one by the other, the reported balance equals about 27 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Salarius Pharmaceuticals, Inc.'s Piotroski F-Score?

Salarius Pharmaceuticals, Inc. (SLRX) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Salarius Pharmaceuticals, Inc.'s earnings high quality?

For every $1 of reported earnings, Salarius Pharmaceuticals, Inc. (SLRX) used $0.39 of operating cash (-$4.8M OCF vs $12.5M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.